Accessibility settings

This paper is in the following e-collection/theme issue:

Formative Evaluation of Digital Health Interventions (5253) Digital Mental Health Interventions, e-Mental Health and Cyberpsychology (3284) Research Instruments, Questionnaires, and Tools (1218) Development of Instruments and Surveys (174) Depression and Mood Disorders; Suicide Prevention (2498) mHealth for Treatment Adherence (624) Patient-Reported Outcome Measures (PROMs) (477)

Published on in Vol 10 (2026)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/85037, first published .
Close-up of hands holding a smartphone with sunlight flare

Supporting the Primary Outcomes of the Mirai Trial for the Adjunctive Digital Therapeutic Rejoyn (CT-152) in the Treatment of Major Depressive Disorder: Meaningful Change Analysis in the Montgomery-Åsberg Depression Rating Scale

Supporting the Primary Outcomes of the Mirai Trial for the Adjunctive Digital Therapeutic Rejoyn (CT-152) in the Treatment of Major Depressive Disorder: Meaningful Change Analysis in the Montgomery-Åsberg Depression Rating Scale

Authors of this article:

Stacie Hudgens1 Author Orcid Image ;   Intan Purnajo1 Author Orcid Image ;   Lysbeth Floden1 Author Orcid Image ;   Steve Hwang2 Author Orcid Image ;   Jessica Ash2 Author Orcid Image ;   Brian Rothman2 Author Orcid Image ;   Austin Speier3 Author Orcid Image ;   Ainslie Forbes2 Author Orcid Image
Article Authors Cited by Tweetations Metrics

Stacie Hudgens   1 , PhD ;   Intan Purnajo   1 , MPH ;   Lysbeth Floden   1 , PhD ;   Steve Hwang   2 , PhD ;   Jessica Ash   2 , PhD ;   Brian Rothman   2 , PhD ;   Austin Speier   3 , AB ;   Ainslie Forbes   2 , PhD

1 Clinical Outcomes Solutions Ltd., Tucson, AZ, United States

2 Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, United States

3 Click Therapeutics, Inc., New York, NY, United States

Corresponding Author: